SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

HSBCs bearish view on CoreWeave has amplified concerns about its debt-heavy data-center expansion, rising financing costs, and potentially slowing AI demand. Traders are split between buying the selloff and anticipating a short squeeze, and warning that credit and insider-selling risks could prolong the decline.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being tied by traders to weakening confidence in Trump and the approaching midterms, alongside concerns about the companys limited business fundamentals and Truth Social. The discussion is broadly bearish, though some traders view the decline as a possible short-term trading bounce.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rebound toward a one-year high and the $30 level is driving discussion, with traders focused on whether the move can break through resistance. Some see momentum from a defensive-sector rotation and pipeline developments ahead of earnings, while others say the stock needs stronger news to sustain a breakout.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is caught in a sharp neocloud and AI-infrastructure selloff as traders weigh Gartners warning about the sectors economics and broader concerns over debt, funding, and project execution. The community is split between expecting further declines and buying an oversold dip; some cite the CEOs assurances about data-center financing, while others point to Horizon 2 delays and weak price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention for a sharp rebound after a tech-led selloff, which traders link to unconfirmed reports of potential U.S.-Iran talks and easing oil prices. The community is split between viewing the move as a bullish reversal and warning it may be a bull trap amid persistent volatility and concerns about tech and AI stocks.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp, extended semiconductor selloff has put SOXX in focus, with traders debating whether fears over AI spending returns, debt and crowded positioning signal a deeper downturn or an oversold bounce. Some see upcoming chip and hyperscaler earnings as a test of demand and capex, while others remain cautious about the sectors technical weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Notable Wednesday Option Activity: ZVRA, KOD, PEN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Zevra Therapeutics, Inc (Symbol: ZVRA), where a total volume of 8,827 contracts has been traded thus far today, a contract volume which is representative of appr...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky

Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 3, 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the...

Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates

Ono Pharmaceutical Co. (OPHLF) delivered earnings and revenue surprises of +60.00% and +5.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...

ZVRA Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Zevra Therapeutics (ZVRA)

On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease...

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics

ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics ZVRA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Zevra Therapeutics PR Newswire NEW YORK, July 28, 2026 Zevra shareholders...

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (Zevra or the Company) (NASDAQ: ZVRA) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA)

Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) PR Newswire NEW YORK, July 27...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA Stock Sinks 23% On EU Setback — Analyst Says Risk Is ‘A Headwind, But Not Insurmountable’

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Zevra plans to request a re-examination and will submit a detailed response.</li><li>H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around the European opportunity.”</li><li>Arimoclomol is already approved and marketed in the U.S. under the brand name MIPLYFFA.</li></ul>Shares of Zevra Therapeutics (ZVRA) fell by as much as 27% on Friday but pared some losses after H.C. Wainwright noted that the company’s recent setback for its drug arimoclomol in Europe was “not insurmountable.”At the time of writing, the stock was down 23%, on track for its worst day since March 2021.<h2 class="st-heading-2">ZVRA’s Setback</h2>On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disorder. &nbsp;The committee concluded that the drug’s effectiveness had not been clearly proven. It cited uncertainties in how the trial data were handled and analyzed, and noted no clear benefit in walking ability or cognition. Although patients already taking miglustat, alongside arimoclomol, showed some positive signs, these were not considered robust enough for the overall population. As a result, the benefits did not outweigh the risks, the committee said. &nbsp;Zevra plans to request a re-examination and will submit a detailed response. CEO Neil F. McFarlane said the company remains “confident in the totality of evidence” and is committed to finding pathways to bring the treatment to European patients.<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around the European opportunity.” The firm maintained its ‘Buy’ rating and $26 price target, noting that Zevra plans to request a re-examination and that this is not the end of the process. Analysts left estimates and valuation unchanged ahead of the company’s August 5 earnings call.Arimoclomol is already approved and marketed in the U.S. under the brand name MIPLYFFA. The FDA cleared it in September 2024 as the first treatment for neurological symptoms of NPC in patients aged 2 years and older, used in combination with miglustat. MIPLYFFA generated $87.4 million in net revenue for the full year 2025 and accounted for a lion’s share of the company's total net revenue of $106.5 million.<h2 class="st-heading-2">How Did ZVRA Retail Traders React?</h2>On Stocktwits, retail sentiment around ZVRA stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user noted that Zevra has not provided details pertaining to the timeline for its further submission.<stembedurl>https://www.stocktwits.com/Smedley1/message/659962885</stembedurl>Another opined that Zevra’s success may come down to whether its drug is superior to privately held pharma company IntraBio’s Aquneursa, also approved for Niemann-Pick disease Type C.<stembedurl>https://www.stocktwits.com/Wahoos/message/659959655</stembedurl><a href="https://stocktwits.com/symbol/ZVRA">ZVRA stock</a> has gained 8% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mnkd-stock-rises-8-on-furoscix-ready-flow-approval-and-50-m-funding-boost/cZZpTilR7zc">MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

Zevra plans to request a re-examination and will submit a detailed response.H.C. Wainwright called the negative opinion on Zevra Therapeutics’ marketing application for arimoclomol “a disappointing outcome that clearly increases the regulatory risk around

On Friday, Zevra announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on its application to market arimoclomol for Niemann-Pick disease type C. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$10.47
Prev Close	$10.16
Open	$10.26
Dividend Yield	0.00%
50-Day Moving Average	$11.42
Beta	0.79
Avg. Volume	965,603.56
PE Ratio	10.96

52-Week High	$15.04
52-Week Low	$8.01
Market Capitalization	$603.34M
EPS (Annual)	$1.35
Price to Book	2.77
Revenue Per Employee	$1.75M

Feed

News

Sentiment

Earnings

Fundamentals

Info

ZVRA Fundamentals